
Search Clinical Trials
The BU-CTSI is a center of expertise providing tools, services and resources to clinical investigators, maximizing the impact of discoveries & speeding the translation of research into improved patient care
Sponsor Condition of Interest |
---|
Anti-thrombotics for Adults Hospitalized With COVID-19 (ACTIV-4)
Matthew Neal MD
Covid19
This is a randomized, open label, adaptive platform trial to compare the effectiveness of
antithrombotic strategies for prevention of adverse outcomes in COVID-19 positive inpatients
expand
This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic strategies for prevention of adverse outcomes in COVID-19 positive inpatients Type: Interventional Start Date: Sep 2020 |
A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis
Caelum Biosciences
AL Amyloidosis
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and
create free light chains that cannot be broken down. These free light chains bind together to
form amyloid fibrils that build up in the extracellular space of organs, affecting the... expand
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine if CAEL-101 improves the overall survival in Patients with cardiac AL Amyloidosis. Type: Interventional Start Date: Aug 2020 |
A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
Pfizer
Respiratory Tract Infection
This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the
efficacy and safety of maternal immunization with RSVpreF against medically attended lower
respiratory tract illness (MA-LRTI) in infants.
expand
This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) in infants. Type: Interventional Start Date: Jun 2020 |
Prevention of Colorectal Cancer Through Multiomics Blood Testing
Freenome Holdings Inc.
Colon Cancer
Rectal Cancer
Colon Neoplasm
Colon Diseases
Colon Lesion
The PREEMPT CRC study is a prospective multi-center observational study to validate a
blood-based test for the early detection of colorectal cancer by collecting blood samples
from average-risk participants who will undergo a routine screening colonoscopy.
expand
The PREEMPT CRC study is a prospective multi-center observational study to validate a blood-based test for the early detection of colorectal cancer by collecting blood samples from average-risk participants who will undergo a routine screening colonoscopy. Type: Observational Start Date: May 2020 |
Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
Vertex Pharmaceuticals Incorporated
Glomerulosclerosis, Focal Segmental
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in subjects
with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).
expand
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in subjects with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS). Type: Interventional Start Date: Jun 2020 |
A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease
Neuraly, Inc.
Parkinson Disease
This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in
subjects with early untreated Parkinson's disease (PD). Evidence suggests NLY01, a pegylated
form of exenatide, may be beneficial in PD and is being developed as a potential treatment... expand
This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD). Evidence suggests NLY01, a pegylated form of exenatide, may be beneficial in PD and is being developed as a potential treatment for neurodegenerative disorders. For more information, please visit: www.PrismPDstudy.com Type: Interventional Start Date: Feb 2020 |
NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of AKCEA-TTR-LRx in Participants With Hereditary...
Ionis Pharmaceuticals, Inc.
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
To evaluate the efficacy and safety of AKCEA-TTR-LRx after administration for 65 weeks to
patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN), as
compared to the NEURO-TTR trial (NCT01737398). For more information, please visit
http://www.neuro-ttransform.com/.... expand
To evaluate the efficacy and safety of AKCEA-TTR-LRx after administration for 65 weeks to patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN), as compared to the NEURO-TTR trial (NCT01737398). For more information, please visit http://www.neuro-ttransform.com/. Type: Interventional Start Date: Jan 2020 |
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of AKCEA-TTR-LRx in Participants With...
Ionis Pharmaceuticals, Inc.
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
To evaluate the efficacy of AKCEA-TTR-LRx compared to placebo for 120 weeks in patients with
ATTR-CM receiving available standard of care (SoC). For more information, please visit
https://www.cardio-ttransform.com/.
expand
To evaluate the efficacy of AKCEA-TTR-LRx compared to placebo for 120 weeks in patients with ATTR-CM receiving available standard of care (SoC). For more information, please visit https://www.cardio-ttransform.com/. Type: Interventional Start Date: Mar 2020 |
Diabetes eConsult Non-Inferiority Study
Boston Medical Center
Diabetes
Flash glucose monitoring is an FDA-approved and widely clinically available, glucose
monitoring technology that is worn on the body and measures glucose values every 15 minutes,
storing this data for up to 14 days. The Freestyle Libre Pro is already used as a diagnostic
technology... expand
Flash glucose monitoring is an FDA-approved and widely clinically available, glucose monitoring technology that is worn on the body and measures glucose values every 15 minutes, storing this data for up to 14 days. The Freestyle Libre Pro is already used as a diagnostic technology in clinical care. It provides a full 24-hour glucose profile for each day that the sensor is worn and that can be correlated with daily activities, medication administration, food intake, and other factors that are contextually relevant in meeting glycemic goals for an individual patient. In this study, patients referred to Endocrinology for specialty diabetes care will be randomized to an in-person visit as is typically done or to wear the Freestyle Libre Pro placed by staff at their primary care clinic. Patients who wear the Freestyle Libre Pro will have a professional interpretation of their glucose data completed by an endocrinologist as well as a remote eConsult completed using this glucose data and information from their medical record. The recommendations from the eConsult regarding medication and lifestyle adjustment as well as potential referral on to see Endocrinology will be implemented by the primary care physician at their clinical discretion. The investigators will utilize glycemic measures including hemoglobin A1c, number of clinical visits (outpatient, inpatient and emergency department) for diabetes care, patient reported outcomes including self-efficacy, and patient and provider assessments of burden to determine if eConsults utilizing flash glucose monitoring technology are non-inferior to in-person visits with a diabetes specialist. Type: Interventional Start Date: Feb 2020 |
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced...
Janssen Research & Development, LLC
Carcinoma, Non-Small-Cell Lung
The purpose of this study is to confirm the tolerability of recommended Phase 2 dose (RP2D)
of lazertinib (Phase 1), to determine the tolerability and identify the recommended Phase 2
combination dose of lazertinib when combined with Amivantamab (Phase 1b), to characterize the... expand
The purpose of this study is to confirm the tolerability of recommended Phase 2 dose (RP2D) of lazertinib (Phase 1), to determine the tolerability and identify the recommended Phase 2 combination dose of lazertinib when combined with Amivantamab (Phase 1b), to characterize the safety and tolerability of lazertinib and Amivantamab combinations at the RP2CD in participants with advanced NSCLC with documented advanced or metastatic EGFR mutation (Phase 1b expansion cohorts A, B and C) and to estimate the antitumor activity of lazertinib and Amivantamab combinations at the RP2CD in participants with advanced NSCLC with documented advanced or metastatic EGFR mutation (Phase 1b expansion cohorts A, B and C). Type: Interventional Start Date: Sep 2019 |
St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Gabapentin
Boston Medical Center
Chronic Pain
Alcohol Use, Unspecified
HIV Infections
This study is a 3-arm pilot, randomized, double-blinded, placebo-controlled study of low-dose
naltrexone and gabapentin versus placebo among HIV-positive persons with heavy alcohol use
and chronic pain to provide estimates of their effects on 1) pain; 2) inflammation; and 3)... expand
This study is a 3-arm pilot, randomized, double-blinded, placebo-controlled study of low-dose naltrexone and gabapentin versus placebo among HIV-positive persons with heavy alcohol use and chronic pain to provide estimates of their effects on 1) pain; 2) inflammation; and 3) measures of HIV control. Participants will be followed for 12 weeks. Assessments of study outcomes will be compared at week 8 (end of treatment phase). Type: Interventional Start Date: Jan 2021 |
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With...
National Cancer Institute (NCI)
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma
Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma
Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma
Ann Arbor Stage IIIA Hodgkin Lymphoma
This phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when
given with combination chemotherapy in treating patients with newly diagnosed stage III or IV
classic Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may... expand
This phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to cancer cells in a targeted way and delivers vedotin to kill them. Chemotherapy drugs, such as doxorubicin, vinblastine, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The addition of nivolumab or brentuximab vedotin to combination chemotherapy may shrink the cancer or extend the time without disease symptoms coming back. Type: Interventional Start Date: Jul 2019 |
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
Novartis Pharmaceuticals
Sickle Cell Disease (SCD)
The purpose of this study is to compare the efficacy and safety of 2 doses of crizanlizumab
(5.0 mg/kg and 7.5 mg/kg) versus placebo in adolescent and adult sickle cell disease (SCD)
patients with history of vaso-occlusive crisis (VOC) leading to healthcare visit.
expand
The purpose of this study is to compare the efficacy and safety of 2 doses of crizanlizumab (5.0 mg/kg and 7.5 mg/kg) versus placebo in adolescent and adult sickle cell disease (SCD) patients with history of vaso-occlusive crisis (VOC) leading to healthcare visit. Type: Interventional Start Date: Jul 2019 |
Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease
Boston University
Alzheimer Disease
Mild Cognitive Impairment
In this multi-center study, the investigators plan to develop a simple blood-based test for
early detection of Alzheimer's disease (AD). The test is based on a single injection of
Pramlintide, an amylin analogue and FDA-approved drug currently used for treatment of
diabetes.... expand
In this multi-center study, the investigators plan to develop a simple blood-based test for early detection of Alzheimer's disease (AD). The test is based on a single injection of Pramlintide, an amylin analogue and FDA-approved drug currently used for treatment of diabetes. The investigative team has provided evidence in humans with full-blown AD and AD-relevant mouse models that a single injection of Pramlintide transiently renders the blood brain barrier (BBB) more permeable to Amyloidbeta (Aß) peptides, allowing their efflux from the brain compartment into the blood. This Aß efflux causes a corresponding transient elevation of blood levels of Aß, the magnitude of which the applicants believe is proportional to the brain amyloid load as determined by AV-45 PET. The measured difference in the level of plasma Aß taken just before and a short time after injection should reveal the magnitude of the transient increase in blood Aß levels. Supportive preliminary data comes from later stage (full-blown) AD patients with more in-depth background studies in Tg2576 and 5X Familial Alzheimer's Disease (FAD) mouse models. If successful for use as an early AD (i.e., at the Mild Cognitive Impairment [MCI] stage) biomarker, this could be a game-changer for both early AD diagnostics and clinical trials aimed at identifying and testing the efficacy of drugs useful for treatment of AD at early stages. If Pramlintide is effective in releasing mobile pools of Aß from the brain into the blood, this could also have some therapeutic potential, with the goal of reducing brain amyloid load. Three groups of particpants will be studied: 1) amnestic MCI with or without positive AD imaging pathology, 2) probable AD with positive imaging AD pathology, and 3) controls who have normal cognition and do not have memory complaints. Type: Interventional Start Date: Feb 2020 |
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
RTOG Foundation, Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC)
This phase II trial with a safety run-in component will evaluate whether the addition of
pembrolizumab to Stereotactic Body Radiation Therapy (SBRT) re-irradiation will improve the
progression-free survival for patients with recurrent or new second primary Head and Neck
Squamous... expand
This phase II trial with a safety run-in component will evaluate whether the addition of pembrolizumab to Stereotactic Body Radiation Therapy (SBRT) re-irradiation will improve the progression-free survival for patients with recurrent or new second primary Head and Neck Squamous Cell Carcinoma (HNSCC). Type: Interventional Start Date: Nov 2018 |
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants...
AbbVie
Multiple Myeloma
A study designed to evaluate the safety and efficacy of venetoclax plus dexamethasone
(VenDex) compared with pomalidomide plus dexamethasone (PomDex) in participants with
t(11;14)-positive Relapsed or Refractory Multiple Myeloma.
expand
A study designed to evaluate the safety and efficacy of venetoclax plus dexamethasone (VenDex) compared with pomalidomide plus dexamethasone (PomDex) in participants with t(11;14)-positive Relapsed or Refractory Multiple Myeloma. Type: Interventional Start Date: Oct 2018 |
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With...
NRG Oncology
Stage II Prostate Adenocarcinoma
This randomized phase III trial studies how well stereotactic body radiation therapy works
compared to intensity-modulated radiation therapy in treating patients with stage IIA-B
prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink
tumors.... expand
This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Stereotactic body radiation therapy may work better in treating patients with prostate cancer. Type: Interventional Start Date: Nov 2017 |
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head...
National Cancer Institute (NCI)
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Head and Neck Squamous Cell Carcinoma
Hypopharyngeal Squamous Cell Carcinoma
Laryngeal Squamous Cell Carcinoma
Oral Cavity Squamous Cell Carcinoma
This phase II/III trial studies how well radiation therapy works with durvalumab or cetuximab
in treating patients with head and neck cancer that has spread to a local and/or regional
area of the body who cannot take cisplatin. Radiation therapy uses high energy x-rays to kill... expand
This phase II/III trial studies how well radiation therapy works with durvalumab or cetuximab in treating patients with head and neck cancer that has spread to a local and/or regional area of the body who cannot take cisplatin. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. It is not known if radiation therapy with durvalumab will work better than the usual therapy of radiation therapy with cetuximab in treating patients with head and neck cancer. Type: Interventional Start Date: Dec 2017 |
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage...
NRG Oncology
Recurrent Non-Small Cell Lung Carcinoma
Stage IV Non-Small Cell Lung Cancer
This randomized phase II/III trial studies how well giving maintenance chemotherapy with or
without local consolidation therapy works in treating patients with stage IV non-small cell
lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium,... expand
This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without local consolidation therapy works in treating patients with stage IV non-small cell lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Local consolidation therapy such as radiation/stereotactic body radiation or surgery may kill cancer cells left after initial treatment. Giving maintenance chemotherapy and local consolidation therapy together may work better than maintenance chemotherapy alone in treating patients with stage IV non-small cell lung cancer. Type: Interventional Start Date: Apr 2017 |
A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases
Mark Gladwin
Sickle Cell Disease
The proposed study is a Phase 2 multi-center, randomized, double-blind, placebo-controlled,
parallel groups study aimed to evaluate the safety, tolerability and the efficacy of
riociguat compared with placebo in patients with sickle cell disease (SCD).
expand
The proposed study is a Phase 2 multi-center, randomized, double-blind, placebo-controlled, parallel groups study aimed to evaluate the safety, tolerability and the efficacy of riociguat compared with placebo in patients with sickle cell disease (SCD). Type: Interventional Start Date: Apr 2017 |
Monitoring Neoadjuvant Chemotherapy Response in Breast Cancer Patients Using Diffuse Optical Spectroscopic...
Boston Medical Center
Breast Cancer
This study seeks to enroll women with breast cancer undergoing neoadjuvant chemotherapy to
evaluate the efficacy of an investigational imaging technology known as Diffuse Optical
Spectroscopy Imaging (DOSI) in predicting patient response to chemotherapy treatment. DOSI is... expand
This study seeks to enroll women with breast cancer undergoing neoadjuvant chemotherapy to evaluate the efficacy of an investigational imaging technology known as Diffuse Optical Spectroscopy Imaging (DOSI) in predicting patient response to chemotherapy treatment. DOSI is a noninvasive imaging method that uses harmless near-infrared light using simple wearable probes held against the skin by transparent dressings to predict tumor metabolic activity. It uses nonionizing radiation, requires no external contrast agent and uses low light exposure to human tissue. DOSI scans can be performed frequently at the bedside in settings such as a doctor's office or infusion center. Type: Interventional Start Date: Jan 2015 |
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
Epstein-Barr Virus Infection
Stage II Nasopharyngeal Carcinoma
Stage III Nasopharyngeal Carcinoma
Stage IVA Nasopharyngeal Carcinoma
Stage IVB Nasopharyngeal Carcinoma
There are two study questions we are asking in this randomized phase II/III trial based on a
blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally
advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard
concurrent... expand
There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if there is no detectable EBV DNA in their plasma, then patients are randomized to either standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and fluorouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in treating patients with nasopharyngeal cancer. Type: Interventional Start Date: Apr 2014 |
Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous...
AIDS Malignancy Consortium
Anal Intraepithelial Neoplasia
High-grade Squamous Intraepithelial Lesion
HIV Infection
This randomized phase III trial studies imiquimod or fluorouracil to see how well they work
compared to observation in treating patients with high-grade anal squamous skin lesions who
are human immunodeficiency virus (HIV)-positive. Biological therapies, such as imiquimod, may... expand
This randomized phase III trial studies imiquimod or fluorouracil to see how well they work compared to observation in treating patients with high-grade anal squamous skin lesions who are human immunodeficiency virus (HIV)-positive. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether imiquimod or fluorouracil is more effective than observation in treating high-grade anal squamous skin lesions. Type: Interventional Start Date: Sep 2015 |
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy...
National Cancer Institute (NCI)
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
This phase II/III trial studies how well radiation therapy works when given together with
cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with
high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous
cell).... expand
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab. Type: Interventional Start Date: Mar 2013 |
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
CHDI Foundation, Inc.
Huntington's Disease
Enroll-HD is a longitudinal, observational, multinational study that integrates two former
Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and
Australasia-while also expanding to include sites in Latin America. More than 20,000
participants... expand
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 20,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and biomarkers for progression and prognosis, identifying clinically-relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies. Periodic cuts of the database are now available to any interested researcher to use in their research - visit www.enroll-hd.org/for-researchers/access-data/ to learn more. Type: Observational [Patient Registry] Start Date: Jul 2012 |
- Previous
- Next